[Nintedanib (Ofev®) in the treatment of idiopathic pulmonary fibrosis]
Molinari L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001398
Spanish
Original Title:
Nintedanib (Ofev®) para el tratamiento de fibrosis pulmonar idiopática
Authors' recommendations:
CONCLUSIONS
High quality evidence did not show that the use of nintedanib in patients with mild or moderate pulmonary fibrosis would decrease mortality when compared with placebo administration. Its benefit would be limited to decreasing the number of exacerbations and forced vital capacity (FVC) worsening.
Moderate quality evidence suggests that its efficacy might be similar to that of pirfenidone, although there are no studies directly comparing both drugs.
The clinical practice guidelines mention it as a treatment option for patients with mild to moderate pulmonary fibrosis. Different health sponsors from developed countries cover it in patients with a FVC above 50% and a carbon monoxide diffusing capacity over 35%; in other cases only if the cost is similar to that of pirfenidone or after a significant reduction in price through bargaining systems.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Idiopathic Pulmonary Fibrosis
- Antifibrotic Agents
- Protein Kinase Inhibitors
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.